Neuroimaging in dementias

Current Opinion in Psychiatry

Volumn 25, Issue 6, 2012, Pages 473-479

  De Souza, Leonardo Cruz ^a,b,c,d   Lehéricy, Stéphane ^a   Dubois, Bruno ^a,b,c,d   Stella, Florindo ^e,f   Sarazin, Marie ^a,b,c,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c INSERM   (France)

^d CNRS   (France)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; Dementia; Neuroimaging

Indexed keywords

AMYLOID PROTEIN; FLUORODEOXYGLUCOSE; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; BRAIN ATROPHY; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; FRONTOTEMPORAL DEMENTIA; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; DEMENTIA; FUNCTIONAL NEUROIMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84867309315     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328357b9ab     Document Type: Review

References (67)

1. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010; 6:98-103.
2. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retro-spective study. Lancet Neurol 2011; 10:785-796.
3. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011; 68:1062-1064.
4. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality i NDex (STAND)-scores correlate with postmortem Braak neuro-fibrillary tangle stage. Neuroimage 2008; 42:559-567.
5. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008; 71:743-749.
6. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommenda-tions from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:257-262.
7. Cuingnet R, Gerardin E, Tessieras J, etal.Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage 2011; 56:766-781.
8. Duara R, Loewenstein DA, Potter E, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 2008; 71:1986-1992.
9. Sabuncu MR, Desikan RS, Sepulcre J, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol 2011; 68:1040-1048.
10. Frisoni GB, Fox NC, Jack CR Jr, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010; 6:67-77.
11. Chincarini A, Bosco P, Calvini P, et al. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. Neuroimage 2011; 58:469-480.
12. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011; 377:1019-1031.
13. Costafreda SG, Dinov ID,Tu Z, etal.Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage 2011; 56:212-219.
14. Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011; 68:1257-1266.
15. Den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133:1163-1172.
16. Sarazin M, Chauvire V, Gerardin E, et al. The amnestic syndrome of hippo-campal type in Alzheimer's disease: an MRI study. J Alzheimers Dis 2010; 22:285-294.
17. Mc Donald CR, Mc Evoy LK, Gharapetian L, etal. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009; 73:457-465.
18. Piguet O, Hornberger M, Mioshi E, Hodges Jr. Behavioural-variant fronto-temporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10:162-172.
19. Seelaar H, Rohrer JD, Pijnenburg YA, etal. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011; 82:476-486.
20. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006-1014.
21. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134:2456-2477.
22. Krueger CE, Dean DL, Rosen HJ, et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer's disease. Alzheimer Dis Assoc Disord 2010; 24:43-48.
23. Lindberg O, Walterfang M, Looi JC, et al. Hippocampal shape analysis in Alzheimer's disease and frontotemporal lobar degeneration subtypes. J Alzheimers Dis 2012; 30:355-365.
24. Josephs KA, Dickson DW. Hippocampal sclerosis in tau-negative frontotem-poral lobar degeneration. Neurobiol Aging 2007; 28:1718-1722. (Pubitemid 47393588)
25. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol 2012; 11:170-178.
26. Mc Keith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872. (Pubitemid 43970103)
27. Rodriguez MJ, Potter E, Shen Q, et al. Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer's disease. Alzheimers Dement 2012; 8:211 -218.
28. Sabattoli F, Boccardi M, Galluzzi S, etal. Hippocampal shape differences in dementiawith Lewy bodies. Neuroimage 2008; 41:699-705.
29. Goos JD, Teunissen CE, Veerhuis R, et al. Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiol Aging 2012; 33:1011e1-10119e.
30. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011; 70:871 -880.
31. Ewers M, Sperling RA, Klunk WE, et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011; 34:430-442.
32. Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010; 6:78-87.
33. Noble JM, Scarmeas N.Application of pet imaging todiagnosisof Alzheimer's disease and mild cognitive impairment. Int Rev Neurobiol 2009; 84:133-149.
34. Jagust W. Molecular neuroimaging in Alzheimer's disease. Neuro Rx 2004; 1:206-212. (Pubitemid 46589352)
35. Habert MO, Horn JF, Sarazin M, et al. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiol Aging 2011; 32:15-23.
36. Rollin-Sillaire A, Bombois S, Deramecourt V, et al. Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic. J Alzheimers Dis 2012; 30:833-845.
37. Scholl M, Almkvist O, Axelman K, etal. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 2011; 32:1388-1399.
38. Mosconi L, Rinne JO, Tsui WH, et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging 2012. [Epub ahead of print]
39. Womack KB, Diaz-Arrastia R, Aizenstein HJ, etal. Temporoparietal hypome-tabolism in frontotemporal lobar degeneration and associated imaging diag-nostic errors. Arch Neurol 2011; 68:329-337.
40. Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64:388-401.
41. Kas A, Uspenskaya O, Lamari F, et al. Distinct brain perfusion pattern associated with CSF biomarkers profile in progressive aphasia. J Neurol Neurosurg Psychiatry 2012; 83:695-698.
42. Kas A, de Souza LC, Samri D, etal. Neural correlates ofcognitive impairment in posterior cortical atrophy. Brain 2011; 134:1464-1478.
43. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortemcorrelatesof in vivo Pi B-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630-1645. (Pubitemid 351806448)
44. Klunk WE, Engler H, Nordberg A, etal. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319. (Pubitemid 38269583)
45. Villemagne VL, Rowe CC. Amyloid imaging. Int Psychogeriatr 2011; 23 (Suppl 2):S41 -S49.
46. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 2011; 10:667-670.
47. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs. FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034-2042.
48. De Souza LC, Corlier F, Habert MO, et al. Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011; 134:2036-2043.
49. Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011; 76:1789-1796.
50. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73:754-760.
51. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133:3336-3348.
52. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76:1085-1090.
53. Kadir A, Almkvista O, Forsberg A, etal. Dynamic changes in PETamyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012; 33:198.e1 -198.e14.
54. Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pitts-burgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011; 134:301-317.
55. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119-128.
56. Fleisher A, Chen K, Liu X, et al. Using positron emission tomography and Florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68:1404-1411.
57. Wolk D, Grachev I, Buckley C, et al. Association between in vivo Fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivocerebral cortical histopathology.Arch Neurol 2011; 68:1398-1403.
58. Mc Khann G, Drachman D, Folstein M, etal. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944. (Pubitemid 14076461)
59. Dubois B, Feldman HH, Jacova C, etal. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-746. (Pubitemid 47058377)
60. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9:1118-1127.
61. Mc Khann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-269.
62. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guide-lines for Alzheimer's disease. Alzheimers Dement 2011; 7:270-279.
63. Sarazin M, de Souza LC, Lehericy S, Dubois B. Clinical and research diagnostic criteria for Alzheimer's disease. Neuroimaging Clin N Am 2012; 22:23-32; viii.
64. Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012; 263:344-361.
65. Douaud G, Jbabdi S, Behrens TE, et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. Neuroimage 2011; 55:880-890.
66. Aisen PS, Petersen RC, Donohue MC, et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010; 6:239-246.
67. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 2011; 7:474-485; e4.